ArticleJournal of thoracic disease2024
Sulforaphane attenuates phosgene-induced acute lung injury via the Nrf2-HO-1/NQO1 pathway.
Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Innovative myeloid ecotropic viral integration site 1-engineered exosome platform combating oxidative stress and inflammation in acute pulmonary damage.Bioengineering & translational medicine · 2026Article
- Recent understanding of immunometabolic remodeling in pulmonary macrophages: homeostasis, chronic respiratory diseases, and therapeutic targeting.Frontiers in pharmacology · 2026Review
- Sulforaphane Repairs Oxidative Stress Damage Induced by Oxidized Fish Oil by ActivatingAquaculture nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sulforaphane (SFN) has been demonstrated to exert a protective role in various diseases. However, the role of SFN in phosgene-induced acute lung injury (P-ALI) remains unclear. This study aimed to explore the role and mechanism of SFN in P-ALI and provide a theoretical basis for the clinical prevention and treatment of P-ALI. Methods: A mouse model of P-ALI was established followed by phosgene gas inhalation at a dose of 4.17 g/m Results: Compared with the control group, destruction of alveolar structure, pulmonary edema, lung tissue inflammation and oxidative stress occurred after phosgene exposure. After the administration of SFN, the massive exudation of red blood cells and significant thickening of alveolar interstitium were ameliorated, the lung tissue inflammation was improved, and oxidative stress level was reduced. Mechanically, SFN could increase the expression of nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2) protein and the downstream heme oxgenase-1 (HO-1) and NAD(P)H:quinone oxidoreductase 1 (NQO1), thereby improving P-ALI. And the Nrf2 inhibitor ML385 attenuated the lung protective effect of SFN. Conclusions: Phosgene inhalation led to edema, inflammation, and oxidative stress of lung tissue in mice. SFN might ameliorate phosgene-induced lung injury through Nrf2-HO-1/NQO1 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.